Is LumiraDx Ltd still operating as a company?

No. The Cayman Islands Grand Court issued a final dissolution order for LumiraDx Limited on September 16, 2024, ending its existence as an independent entity after its point-of-care diagnostics platform was sold to Roche in July 2024 for $353.5 million.

Who owns LumiraDx's technology now?

Roche Diagnostics acquired LumiraDx's point-of-care technology platform and operating subsidiaries via a pre-pack administration sale that closed July 29, 2024, for an aggregate $353.5 million, after LumiraDx's UK entities entered administration in December 2023.

Can I still get a job at LumiraDx?

Only as a Roche employee. LumiraDx Ltd is dissolved as of September 16, 2024; remaining staff and product lines were absorbed into Roche Diagnostics, and LumiraDx SAS in France was formally merged into Roche Diagnostics France effective July 1, 2025.

Why did LumiraDx collapse?

Revenue fell from a COVID-driven peak of about $420 million in 2021 to roughly $20 million per quarter by 2023, a 70% year-on-year decline, leaving the company unable to service about $350 million in debt after a 2022 sale process drew zero bids.

Did LumiraDx shareholders lose their investment?

Nasdaq suspended trading in LMDX shares on January 9, 2024, ahead of delisting, and the company went through pre-pack administration starting December 29, 2023; the brief found no evidence of meaningful recovery for former public shareholders.

Is Roche's LumiraDx deal a monopoly concern?

No. The UK Competition and Markets Authority cleared Roche's acquisition after a Phase 1 review on July 19, 2024, describing LumiraDx as 'a small competitor' to Roche in point-of-care in-vitro diagnostic tests like INR and D-dimer.

Biotech tools companies · absorbed · United Kingdom

LumiraDx Ltd

lumiradx.com ↗

UK point-of-care diagnostics maker, now dissolved after selling tech to Roche.

Little protection left

Assessed 25 July 2026 · Evidence as of 25 July 2026

Not much stands between this business and its pressures.

On the recordSince 25 July 2026 · Checkable from July 1, 2025 · Every call on the record Checkpoint: French subsidiary merger completion tied to wind-down

The call

LumiraDx Ltd no longer exists as an operating company; its technology now sits inside Roche Diagnostics.

LumiraDx made fast diagnostic tests for doctors' offices and hospitals, but when COVID demand dried up after 2021, the company's sales collapsed from $420 million to around $20 million per quarter. The company ran out of money, could not raise new funding, and was shut down in a court-ordered process in the Cayman Islands. Roche, a giant Swiss pharmaceutical company, bought the company's core testing technology for about $353 million in July 2024, so any remaining LumiraDx operations or jobs are now actually Roche operations. If you see a job posting with the LumiraDx name, check whether it is actually a Roche Diagnostics position under a different label, because the original LumiraDx company no longer exists.

Why

AI pressure: None apparent. AI diagnostics tools played no role in the collapse; debt and a COVID demand crash did the damage. Could AI do the core job? Only partly.

Bigger players: Roche Diagnostics. Roche bought the point-of-care platform and operating subsidiaries for $353.5M after LumiraDx's own sale process drew zero bids. Could a giant copy it? Yes, easily.

What protects it. None. The Cayman court dissolved the entity on September 16, 2024; no independent operations remain.

What would change this call

Any job posting or product page using 'LumiraDx' name after 2024. Would show whether the brand persists only as a Roche-owned label or a separate reputational risk.
Roche's product roadmap announcements for former LumiraDx POC devices. Indicates whether Roche continues, rebrands, or discontinues the platform.
Completion of FTI Consulting liquidation and French subsidiary merger by July 2025. Confirms full wind-down of the legacy LumiraDx corporate entity.

Key numbers

Revenue peak $420M in FY2021 (2021-12-31)
Quarterly revenue fell to ~$20M by 2023 (2023-12-31)
Roche paid $353.5M for the platform (2024-07-29)

Named risks

Company is legally dissolved with no independent operations, capital, or roadmap as of September 16, 2024. Severity: high
Any 'LumiraDx' job postings or brand use may actually be Roche entities, creating identity confusion for job seekers. Severity: medium
Ongoing insolvency wind-down of remaining non-Roche subsidiaries could trigger creditor claims through 2026. Severity: low
Former LMDX shareholders appear to have received minimal or no recovery from the administration process. Severity: medium

Rivals, as read in July 2026

Rival	Direction	Evidence
Roche Diagnostics	losing to	Roche acquired LumiraDx's entire point-of-care platform for $353.5M, closed July 29, 2024
Abbott	losing to	Historically outcompeted by Abbott's i-STAT and ID NOW platforms in point-of-care diagnostics scale
Danaher (Cepheid)	losing to	Larger molecular point-of-care incumbent in infectious disease testing, including TB segment

Questions people ask

Is LumiraDx Ltd still operating as a company?: No. The Cayman Islands Grand Court issued a final dissolution order for LumiraDx Limited on September 16, 2024, ending its existence as an independent entity after its point-of-care diagnostics platform was sold to Roche in July 2024 for $353.5 million.
Who owns LumiraDx's technology now?: Roche Diagnostics acquired LumiraDx's point-of-care technology platform and operating subsidiaries via a pre-pack administration sale that closed July 29, 2024, for an aggregate $353.5 million, after LumiraDx's UK entities entered administration in December 2023.
Can I still get a job at LumiraDx?: Only as a Roche employee. LumiraDx Ltd is dissolved as of September 16, 2024; remaining staff and product lines were absorbed into Roche Diagnostics, and LumiraDx SAS in France was formally merged into Roche Diagnostics France effective July 1, 2025.
Why did LumiraDx collapse?: Revenue fell from a COVID-driven peak of about $420 million in 2021 to roughly $20 million per quarter by 2023, a 70% year-on-year decline, leaving the company unable to service about $350 million in debt after a 2022 sale process drew zero bids.
Did LumiraDx shareholders lose their investment?: Nasdaq suspended trading in LMDX shares on January 9, 2024, ahead of delisting, and the company went through pre-pack administration starting December 29, 2023; the brief found no evidence of meaningful recovery for former public shareholders.
Is Roche's LumiraDx deal a monopoly concern?: No. The UK Competition and Markets Authority cleared Roche's acquisition after a Phase 1 review on July 19, 2024, describing LumiraDx as 'a small competitor' to Roche in point-of-care in-vitro diagnostic tests like INR and D-dimer.

Timeline

2025-07-01LumiraDx SAS formally merged into Roche Diagnostics France
2024-09-16Cayman Islands Grand Court issues final dissolution order for LumiraDx Limited
2024-07-29Roche closes acquisition of LumiraDx point-of-care platform for $353.5M
2024-07-19UK CMA clears Roche/LumiraDx deal after Phase 1 review
2024-01-09Nasdaq suspends trading in LMDX shares ahead of delisting
2023-12-29Secured creditors call in loans; UK entities enter pre-pack administration
2023-01-31Company cuts approximately 40% of its workforce
2022-12-31Sale process attracts zero bids
2021-09-29LMDX begins trading on Nasdaq via SPAC merger valued at $3.0 billion
2014-01-01LumiraDx founded by Ron Zwanziger, Dave Scott, and Jerry McAleer

Revision history

25 July 2026

First assessed. Little protection left. The text above is fixed as of this date and is not edited afterwards.

In the same band

Singular Genomics Synthego Corporation Standard BioTools